Abstract |
Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4.
|
Authors | Howraman Meteran, Louise Lindhardt Tønnesen, Pradeesh Sivapalan, Truls Sylvan Ingebrigtsen, Jens-Ulrik Stæhr Jensen |
Journal | Breathe (Sheffield, England)
(Breathe (Sheff))
Vol. 18
Issue 1
Pg. 210178
(Mar 2022)
ISSN: 1810-6838 [Print] England |
PMID | 36338257
(Publication Type: Journal Article)
|
Copyright | Copyright ©ERS 2022. |